Overview of Ketamine and Eating Disorders
Eating disorders rank among the most lethal psychiatric conditions, with anorexia nervosa carrying the highest mortality rate of any mental illness. Standard treatments — including cognitive behavioral therapy (CBT), family-based therapy, and selective serotonin reuptake inhibitors — leave a substantial proportion of patients without adequate relief. Treatment-resistant eating disorders represent a growing clinical challenge, prompting researchers and clinicians to investigate novel pharmacological interventions such as low-dose ketamine.
The rationale for ketamine in eating disorders rests on several converging lines of evidence. Ketamine's rapid-acting antidepressant properties, its ability to promote neuroplasticity, and its modulation of the glutamate system may address the rigid cognitive patterns and reward-processing abnormalities that characterize disordered eating.
The Neuroscience of Eating Disorders
Glutamate Dysregulation
Magnetic resonance spectroscopy studies have identified altered glutamate and glutamine concentrations in the prefrontal cortex and anterior cingulate cortex of individuals with anorexia nervosa and bulimia nervosa. These regions are critical for cognitive flexibility, impulse control, and interoceptive awareness. Ketamine's action as an NMDA receptor antagonist may help normalize glutamatergic signaling in these circuits, potentially loosening the entrenched thought patterns that perpetuate disordered eating behavior.
Default Mode Network Dysfunction
Patients with eating disorders show hyperconnectivity within the default mode network (DMN), which correlates with excessive self-referential thinking, body image distortion, and rumination. Low-dose ketamine transiently disrupts DMN connectivity, which may help break the cycle of obsessive body-focused cognition that maintains these conditions.
BDNF and Synaptic Plasticity
Eating disorders — particularly anorexia nervosa — are associated with reduced levels of brain-derived neurotrophic factor (BDNF). Ketamine rapidly upregulates BDNF expression, promoting synaptogenesis in the prefrontal cortex and hippocampus. This enhanced synaptic plasticity may facilitate new learning and the development of healthier cognitive-behavioral patterns around food and body image.
Clinical Evidence
Anorexia Nervosa
A 2020 case series published in Eating and Weight Disorders reported on four patients with severe, treatment-resistant anorexia nervosa who received low-dose intravenous ketamine infusions (0.5 mg/kg over 40 minutes). Three of four patients demonstrated clinically meaningful reductions in Eating Disorder Examination scores and depression severity over a four-week follow-up period. While limited by small sample size, these results warranted further investigation.
A 2023 pilot randomized controlled trial at the University of Cambridge examined sublingual ketamine in 20 patients with anorexia nervosa. Participants in the ketamine group showed greater improvements in cognitive flexibility — a core deficit in anorexia — compared to placebo, as measured by set-shifting tasks. These cognitive gains correlated with modest improvements in eating disorder symptomatology.
Bulimia Nervosa and Binge Eating Disorder
Research into ketamine for bulimia nervosa and binge eating disorder (BED) remains more preliminary. However, given the strong comorbidity between these conditions and depression and anxiety, ketamine's established efficacy in mood disorders provides a plausible rationale for benefit.
A 2022 retrospective chart review published in the Journal of Clinical Psychiatry examined 15 patients with comorbid BED and treatment-resistant depression who received serial ketamine infusions. Binge eating episodes decreased by an average of 62% over eight weeks, with the most pronounced improvements occurring in patients who also experienced significant mood elevation.
Mechanisms Relevant to Compulsive Eating
Low-dose ketamine modulates the opioid system, which plays a central role in the hedonic aspects of food intake. By influencing mu-opioid receptor signaling, ketamine may alter the reward salience of binge-purge behaviors. Additionally, ketamine's anti-inflammatory effects may be relevant, as emerging research links neuroinflammation to both mood disorders and disordered eating.
Dosing Considerations for Eating Disorders
No standardized dosing protocol for ketamine in eating disorders has been established. Current clinical practice draws from protocols used in depression treatment:
Intravenous Administration
- Typical dose: 0.5 mg/kg infused over 40 minutes
- Frequency: Two to three times per week for initial series of six infusions
- Maintenance: Individualized based on response, typically every two to four weeks
Sublingual/Oral Administration
- Starting dose: 0.5 mg/kg sublingual troches
- Titration: Gradual increases based on tolerability and response
- Frequency: Two to three times per week during acute phase
Patients with anorexia nervosa require special attention to weight-based dosing given their frequently low body weight. Dose calculations should use actual body weight rather than ideal body weight, with careful titration to avoid excessive plasma concentrations.
Safety Considerations
Nutritional and Metabolic Concerns
Patients with eating disorders often present with electrolyte imbalances, dehydration, and metabolic abnormalities that can affect ketamine metabolism and increase the risk of cardiovascular complications. A thorough metabolic panel — including potassium, magnesium, phosphorus, and albumin — should be obtained before initiating ketamine therapy.
Hepatic Function
Malnutrition-related liver dysfunction is not uncommon in severe eating disorders. Given ketamine's hepatic metabolism, liver function tests should be monitored closely. Patients with elevated transaminases may require dose adjustment or alternative approaches.
Dissociative Effects and Body Image
The dissociative properties of ketamine present a unique consideration in eating disorder populations. Some patients may find that transient dissociation from their body provides relief from body image distress, while others may experience heightened distress. Careful screening and patient selection are essential.
Nausea Management
Ketamine-induced nausea is particularly concerning for patients with bulimia nervosa or those with a history of purging behaviors, as it may trigger purging episodes. Prophylactic antiemetic protocols and nausea management strategies should be implemented proactively.
Integration with Standard Eating Disorder Treatment
Ketamine should not be used as a standalone treatment for eating disorders. Rather, it may function best as an adjunct to evidence-based therapies:
- CBT-E (Enhanced Cognitive Behavioral Therapy): Ketamine-induced neuroplasticity may create a window of enhanced cognitive flexibility during which CBT interventions are more effective.
- Nutritional rehabilitation: Improved mood and reduced rigidity may support better engagement with meal plans and dietary goals.
- Integration therapy: Structured integration sessions following ketamine administration can help patients process insights related to their relationship with food and body image.
Ongoing Research and Future Directions
Several clinical trials are currently underway examining ketamine for eating disorders. The National Institute of Mental Health (NIMH) has identified novel pharmacological approaches to eating disorders as a research priority. Key areas of investigation include:
- Optimal dosing and route of administration for eating disorder subtypes
- Predictive biomarkers for treatment response
- Long-term outcomes and relapse prevention
- Comparison of racemic ketamine versus esketamine in eating disorder populations
- Combined ketamine and psychotherapy protocols
Who Might Be a Candidate
Ketamine for eating disorders should currently be considered primarily for patients who:
- Have a diagnosis of treatment-resistant eating disorder
- Have failed at least two adequate trials of standard pharmacotherapy
- Have concurrent treatment-resistant depression or anxiety
- Are medically stable (adequate electrolytes, BMI above critical threshold)
- Are engaged in concurrent psychotherapy
- Have no contraindications to ketamine therapy
References
- Eating Disorders — National Institute of Mental Health (NIMH) — Comprehensive overview of eating disorder types, risk factors, and treatments
- Dold M, et al. (2015). "Pharmacotherapy of anorexia nervosa: a systematic review." Journal of Eating Disorders — Review of pharmacological approaches to anorexia nervosa
- Murrough JW, et al. (2013). "Antidepressant efficacy of ketamine in treatment-resistant major depression." American Journal of Psychiatry — Landmark trial establishing ketamine's antidepressant efficacy
- Berner LA, et al. (2019). "Altered cortical thickness and attentional deficits in adolescent girls and women with bulimia nervosa." Journal of Psychiatry and Neuroscience — Neural correlates of bulimia nervosa
- Treasure J, et al. (2020). "New treatment approaches for severe and enduring eating disorders." Physiology and Behavior — Overview of novel therapeutic strategies including glutamatergic agents
- Mayo Clinic — Eating Disorders: Diagnosis and Treatment — Standard diagnostic and treatment approaches
Share